Table 1 Patient characteristics in the platelet population and split by baseline platelet count quintile. Mean ± standard deviation or count (%) shown
Characteristics | Whole Sample (N = 1796) | Platelet Count Quintile Group 1: < 173 (N = 363) | Platelet Count Quintile Group 2: > = 173 to < 205 (N = 356) | Platelet Count Quintile Group 3: > = 205 to < 234 (N = 354) | Platelet Count Quintile Group 4: > = 234 to < 272 (N = 364) | Platelet Count Quintile Group 5: > = 272 (N = 359) |
|---|---|---|---|---|---|---|
Age, years | 66 ± 8 | 67 ± 7 | 66 ± 8 | 66 ± 8 | 65 ± 8 | 65 ± 8 |
Female | 683 (38%) | 65 (18%) | 108 (30%) | 148 (42%) | 170 (47%) | 192 (53%) |
Race | ||||||
 White | 1608 (90%) | 334 (92%) | 316 (89%) | 319 (90%) | 328 (90%) | 311 (87%) |
 Asian | 22 (1%) | 5 (1%) | 5 (1%) | 3 (< 1%) | 1 (< 1%) | 8 (2%) |
 Other | 166 (9%) | 24 (7%) | 35 (10%) | 32 (9%) | 35 (10%) | 40 (10%) |
Body Mass Index (BMI), kg/m2 | 31 ± 7 | 31 ± 6 | 31 ± 7 | 30 ± 7 | 31 ± 7 | 29 ± 7 |
 Underweight (BMI < 18.5 kg/m2) | 30 (2%) | 5 (1%) | 5 (1%) | 7 (2%) | 4 (1%) | 9 (3%) |
 Normal/Overweight (BMI 18.5–30 kg/m2) | 878 (49%) | 157 (43%) | 159 (45) | 178 (50) | 188 (52%) | 196 (54%) |
 Obese (BMI ≥ 30 kg/m2) | 888 (49%) | 201 (55%) | 192 (54%) | 169 (48%) | 172 (47%) | 154 (43%) |
FEV1, % predicted | 59 ± 7 | 59 ± 7 | 60 ± 7 | 59 ± 7 | 60 ± 7 | 59 ± 7 |
Post-bronchodilator FEV1, L | 1.7 ± 0.4 | 1.8 ± 0.4 | 1.8 ± 0.4 | 1.7 ± 0.4 | 1.7 ± 0.4 | 1.6 ± 0.4 |
Current Smokers | 891 (50%) | 170 (47%) | 176 (49%) | 175 (49%) | 184 (51%) | 186 (52%) |
Pack years smoked | 52 ± 29 | 55 ± 31 | 52 ± 28 | 51 ± 30 | 53 ± 29 | 50 ± 27 |
Oxygen Therapy | 78 (4%) | 18 (5%) | 10 (3%) | 14 (4%) | 21 (6%) | 15 (4%) |
Hematocrit, % | 43 ± 5 | 44 ± 5 | 44 ± 4 | 43 ± 4 | 42 ± 4 | 41 ± 5 |
Anemia: Hematocrit < 39% (men) or < 36% (women) | 212 (12%) | 38 (10%) | 34 (10%) | 34 (10%) | 45 (12%) | 61 (17%) |
Previous medical history | ||||||
 Hypertension | 1630 (91%) | 342 (94%) | 326 (92%) | 312 (88%) | 320 (88%) | 330 (92%) |
 Coronary arterial disease | 877 (49%) | 211 (58%) | 195 (55%) | 162 (46%) | 161 (44%) | 148 (41%) |
 Congestive heart failure | 159 (9%) | 38 (10%) | 36 (10%) | 29 (8%) | 33 (9%) | 23 (6%) |
 Stroke | 138 (8%) | 20 (6%) | 27 (8%) | 27 (8%) | 32 (9%) | 32 (9%) |
 Diabetes | 697 (39%) | 158 (44%) | 138 (39%) | 129 (36%) | 141 (39%) | 131 (36%) |
Pre-study COPD therapy | ||||||
 Inhaled Corticosteroid | 860 (48%) | 172 (47%) | 155 (44%) | 187 (53%) | 163 (45%) | 183 (51%) |
 Long-acting anticholinergic | 542 (30%) | 107 (29%) | 94 (26%) | 110 (31%) | 110 (30%) | 121 (34%) |
 Long-acting beta-2 agonist | 802 (45%) | 161 (44%) | 144 (40%) | 170 (48%) | 154 (42%) | 173 (48%) |
Concomitant cardiovascular therapy | ||||||
 Any Medication | 1755 (98%) | 360 (> 99%) | 351 (99%) | 345 (97%) | 354 (97%) | 345 (96%) |
 Antithrombotic/coagulant | 1225 (68%) | 265 (73%) | 264 (74%) | 238 (67%) | 228 (63%) | 230 (64%) |
 Antiplatelet therapy | 1156 (64%) | 246 (68%) | 248 (70%) | 223 (63%) | 220 (60%) | 219 (61%) |
 Statins | 1362 (83%) | 282 (78%) | 274 (77%) | 271 (77%) | 274 (75%) | 261 (73%) |
 Beta-blockers | 837 (47%) | 197 (54%) | 182 (51%) | 153 (43%) | 162 (45%) | 143 (40%) |
Randomization Group | ||||||
 Placebo | 469 (26%) | 79 (22%) | 88 (25%) | 115 (32%) | 96 (26%) | 91 (25%) |
 Fluticasone Furoate | 449 (25%) | 94 (26%) | 87 (24%) | 87 (25%) | 93 (26%) | 88 (25%) |
 Vilanterol | 436 (24%) | 101 (28%) | 88 (25%) | 65 (18%) | 89 (24%) | 93 (26%) |
 Fluticasone + Vilanterol | 442 (25%) | 89 (25%) | 93 (26%) | 87 (25%) | 86 (24%) | 87 (24%) |